| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01313650 | A 24-week Evaluation of GSK573719/Vilanterol (62.5/25mcg) and Components in COPD | PHASE3 | COMPLETED | 1,538 | — | — | Mar 1, 2011 | Apr 5, 2012 | Aug 6, 2018 | 165 | United States, Bulgaria +11 |
FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 measurements were taken electronically by spirometry on Days 2, 28, 56, 84, 112, 168, and 169. Baseline is defined as the mean of the assessments made 30 minutes pre-dose and 5 minutes pre-dose on Treatment Day 1. Trough FEV1 is defined as the mean of the FEV1 values obtained at 23 and 24 hours after the previous morning's dosing (ie., trough FEV1 on Day 169 is the mean of the FEV1 values obtained 23 and 24 hours after the morning dosing on Day 168). Change from Baseline at a particular visit was calculated as the trough FEV1 at that visit minus Baseline. Analysis was performed using a repeated measures model with covariates of treatment, Baseline , smoking status, center group, day, and day by Baseline and day by treatment interactions. ITT=Intent-to-Treat; par.=participants.
| Arm | Type | Description |
|---|---|---|
| GSK573719/GW642444 | EXPERIMENTAL | 62.5/25mcg |
| GSK573719 | EXPERIMENTAL | 62.5mcg |
| GW642444 | EXPERIMENTAL | 25mcg |
| Placebo | PLACEBO_COMPARATOR | Placebo |
| Name | Type | Description |
|---|---|---|
| 62.5/25mcg | DRUG | GSK573719/GW64244 |
| 62.5mcg | DRUG | GSK573719 |
| 25mcg | DRUG | GW642444 |
| Placebo | DRUG | Placebo |
Inclusion Criteria: * Diagnosis of COPD * 10 pack-year or greater history of cigarette smoking * Post-bronchodilator FEV1/FVC of \<0.7 * Predicted FEV1 of 70% of normal or less * Modified Medical Research Council (mMRC) dyspnea score of 2 or greater Exclusion Criteria: * Women who are pregnant, l...